Dauntless, Aegis sign licensing agreement for Intravail drug delivery technology

Dauntless Pharmaceuticals, Inc. (Dauntless), a biopharmaceutical company focused on the development of specialty drugs and Aegis Therapeutics, LLC (Aegis) today announced a licensing agreement providing Dauntless' access to Aegis' Intravail® drug delivery technology for an undisclosed oncology application and an option for three additional drugs. Financial terms were not disclosed.

Joel F. Martin, President and CEO of Dauntless commented, "We are fortunate to be able to access Aegis' proprietary Intravail® drug delivery technologies for an application that will benefit cancer patients. We have the option of licensing the Intravail® technology for additional drugs and are looking at a number of exciting opportunities."

Edward T. Maggio, Chief Executive Officer of Aegis added, "The team at Dauntless has a track record of rapid, cost-effective clinical development and we are delighted to work with them on this new venture. Dauntless has several innovative ideas to develop additional drugs formulated with Intravail® and we are excited by the prospects of expanding the portfolio."